deferoxamine has been researched along with Ventricular Dysfunction, Left in 16 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Beta-thalassemia major (beta-TM), patients, asymptomatic and with preserved left ventricular ejection fraction (LVEF) were studied echocardiographically." | 5.36 | Effect of combined chelation therapy with deferiprone and deferoxamine on left ventricular diastolic function in adult beta-thalassemia major patients. ( Farmaki, K; Fragatou, S; Kremastinos, D; Kyrzopoulos, S; Paraskevaidis, I; Tsiapras, D; Voudris, V, 2010) |
| "In patients with severe myocardial siderosis and impaired LV function, combined chelation therapy with subcutaneous deferoxamine and oral deferiprone reduces myocardial iron and improves cardiac function." | 5.13 | Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. ( Agus, A; Dessi, C; Galanello, R; Nair, SV; Pennell, DJ; Pibiri, M; Smith, GC; Tanner, MA; Walker, JM; Westwood, MA, 2008) |
| " We used cardiovascular magnetic resonance (CMR) to assess the prevalence of myocardial iron overload and ventricular dysfunction in a large cohort of TM patients maintained on conventional chelation treatment with deferoxamine." | 3.73 | Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. ( Anderson, LJ; Dessi, C; Galanello, R; Nair, SV; Pennell, DJ; Smith, GC; Tanner, MA; Walker, JM; Westwood, MA, 2006) |
| "In patients with thalassemia major (TM) who are non-compliant with long-term deferoxamine (DFO) chelation, survival is limited mainly because of cardiac complications of transfusional siderosis." | 3.72 | Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. ( Berant, M; Hershko, C; Miskin, H; Tamary, H; Yaniv, I, 2003) |
| "Strict lifelong adherence to the standard transfusion and deferoxamine therapy reduces considerably the occurrence of heart failure, LV dysfunction and pericarditis, prevents early heart failure and pulmonary hypertension, but does not eliminate completely cardiac disease in patients with thalassemia major." | 3.72 | Cardiac status in well-treated patients with thalassemia major. ( Aessopos, A; Diamanti-Kandaraki, E; Farmakis, D; Fragodimitri, C; Hatziliami, A; Joussef, J; Karabatsos, F; Karagiorga, M; Meletis, J; Mitilineou, E, 2004) |
| "Iron overload is one of the major causes of morbidity and death in patients undergoing chronic transfusion therapy." | 2.48 | Iron chelation therapy in the management of transfusion-related cardiac iron overload. ( Fernandes, JL, 2012) |
| "Beta-thalassemia major (beta-TM), patients, asymptomatic and with preserved left ventricular ejection fraction (LVEF) were studied echocardiographically." | 1.36 | Effect of combined chelation therapy with deferiprone and deferoxamine on left ventricular diastolic function in adult beta-thalassemia major patients. ( Farmaki, K; Fragatou, S; Kremastinos, D; Kyrzopoulos, S; Paraskevaidis, I; Tsiapras, D; Voudris, V, 2010) |
| "The incidence of cardiac death in both groups was analyzed." | 1.33 | Survival in thalassaemia major patients. ( Efthimiadis, GK; Giannakoulas, GA; Hassapopoulou, HP; Karvounis, HI; Louridas, GE; Parharidis, GE; Tsikaderis, DD, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (68.75) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelmoktader, AM | 1 |
| Azer, HY | 1 |
| Nijjar, PS | 1 |
| Vongooru, H | 1 |
| Tamene, A | 1 |
| Valeti, U | 1 |
| Masri, C | 1 |
| Tauchenová, L | 1 |
| Křížová, B | 1 |
| Kubánek, M | 1 |
| Fraňková, S | 1 |
| Melenovský, V | 1 |
| Tintěra, J | 1 |
| Kautznerová, D | 1 |
| Malušková, J | 1 |
| Jirsa, M | 1 |
| Kautzner, J | 1 |
| Luckie, M | 1 |
| Irwin, B | 1 |
| Nair, S | 1 |
| Greenwood, J | 1 |
| Khattar, R | 1 |
| Sugishita, K | 1 |
| Asakawa, M | 1 |
| Usui, S | 1 |
| Takahashi, T | 1 |
| Tsiapras, D | 1 |
| Fragatou, S | 1 |
| Farmaki, K | 1 |
| Kyrzopoulos, S | 1 |
| Paraskevaidis, I | 1 |
| Voudris, V | 1 |
| Kremastinos, D | 1 |
| Fernandes, JL | 1 |
| Miskin, H | 1 |
| Yaniv, I | 1 |
| Berant, M | 1 |
| Hershko, C | 1 |
| Tamary, H | 1 |
| Aessopos, A | 1 |
| Farmakis, D | 1 |
| Hatziliami, A | 1 |
| Fragodimitri, C | 1 |
| Karabatsos, F | 1 |
| Joussef, J | 1 |
| Mitilineou, E | 1 |
| Diamanti-Kandaraki, E | 1 |
| Meletis, J | 1 |
| Karagiorga, M | 1 |
| Anderson, LJ | 2 |
| Westwood, MA | 3 |
| Holden, S | 1 |
| Davis, B | 1 |
| Prescott, E | 1 |
| Wonke, B | 1 |
| Porter, JB | 1 |
| Walker, JM | 3 |
| Pennell, DJ | 3 |
| Tanner, MA | 2 |
| Galanello, R | 2 |
| Dessi, C | 2 |
| Smith, GC | 2 |
| Nair, SV | 2 |
| Efthimiadis, GK | 1 |
| Hassapopoulou, HP | 1 |
| Tsikaderis, DD | 1 |
| Karvounis, HI | 1 |
| Giannakoulas, GA | 1 |
| Parharidis, GE | 1 |
| Louridas, GE | 1 |
| Cagirci, G | 1 |
| Tufekcioglu, O | 1 |
| Yetim, M | 1 |
| Schröder, C | 1 |
| Heintz, A | 1 |
| Pexa, A | 1 |
| Rauen, U | 1 |
| Deussen, A | 1 |
| Janower, S | 1 |
| Rosmorduc, O | 1 |
| Cohen, A | 1 |
| Agus, A | 1 |
| Pibiri, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Placebo Controlled, Double Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance[NCT00103753] | Phase 4 | 65 participants | Interventional | 2004-05-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for deferoxamine and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Iron chelation therapy in the management of transfusion-related cardiac iron overload.
Topics: Benzoates; Cardiomyopathy, Dilated; Chelation Therapy; Cross-Sectional Studies; Deferasirox; Deferip | 2012 |
[Cardiac involvement in hemochromatosis].
Topics: Algorithms; Chelating Agents; Deferoxamine; Diagnosis, Differential; Dilatation, Pathologic; Echocar | 2007 |
1 trial available for deferoxamine and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
Topics: Administration, Oral; Adult; beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Drug The | 2008 |
13 other studies available for deferoxamine and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Usefulness of pulsed wave tissue doppler imaging in assessment of left ventricular functions in children with beta-thalassemia major.
Topics: beta-Thalassemia; Chelating Agents; Child; Deferoxamine; Echocardiography, Doppler; Female; Humans; | 2013 |
Improvement in Left Ventricular Function Despite No Change in T2* with Iron Chelation in Secondary Hemochromatosis.
Topics: Adult; Anemia, Aplastic; Deferiprone; Deferoxamine; Echocardiography; Hemochromatosis; Humans; Iron | 2015 |
Successful Treatment of Iron-Overload Cardiomyopathy in Hereditary Hemochromatosis With Deferoxamine and Deferiprone.
Topics: Cardiomyopathies; Deferiprone; Deferoxamine; Ferritins; Heart Failure; Hemochromatosis; Hemochromato | 2016 |
Left ventricular non-compaction in identical twins with thalassaemia and cardiac iron overload.
Topics: beta-Thalassemia; Deferoxamine; Diseases in Twins; Echocardiography; Female; Ferritins; Genetic Pred | 2009 |
A case of iron overload cardiomyopathy: beneficial effects of iron chelating agent and calcium channel blocker on left ventricular dysfunction.
Topics: Aged, 80 and over; Calcium Channel Blockers; Cardiomyopathies; Deferoxamine; Ferritins; Humans; Iron | 2009 |
Effect of combined chelation therapy with deferiprone and deferoxamine on left ventricular diastolic function in adult beta-thalassemia major patients.
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ec | 2010 |
Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation.
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Catheterization, Central Venous; Chelation Therapy; Deferox | 2003 |
Cardiac status in well-treated patients with thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Cardiac Output; Child; Deferoxamine; Echocar | 2004 |
Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance.
Topics: Adult; Cardiomyopathies; Case-Control Studies; Deferoxamine; Female; Humans; Infusions, Intravenous; | 2004 |
Myocardial iron loading in patients with thalassemia major on deferoxamine chelation.
Topics: beta-Thalassemia; Cardiomyopathies; Chi-Square Distribution; Deferoxamine; Female; Ferritins; Humans | 2006 |
Survival in thalassaemia major patients.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Death; Deferoxamine; Echocardiography, Doppl | 2006 |
Iron chelating in thalassaemia with left ventricular dysfunction.
Topics: Adult; beta-Thalassemia; Deferoxamine; Dyspnea; Female; Humans; Iron Chelating Agents; Ventricular D | 2006 |
Preclinical evaluation of coronary vascular function after cardioplegia with HTK and different antioxidant additives.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Biomarkers; Bradykinin; Cardioplegic Solutions; Chrom | 2007 |